EU/US Properties Organoleptics Cosmetics Suppliers Safety Safety in use Safety references References Other Blenders Uses Occurrence Synonyms Articles Notes
 

magnesium orotate
4-pyrimidinecarboxylic acid, 1,2,3,6-tetrahydro-2,6-dioxo-, magnesium salt (2:1)

Supplier Sponsors

CAS Number: 34717-03-8Picture of molecule3D/inchi
Other(deleted CASRN):11097-30-6
ECHA EINECS - REACH Pre-Reg:252-167-6
FDA UNII: GI96W46M5A
MDL:MFCD00039120
Molecular Weight:334.48442000
Formula:C10 H6 Mg N4 O8
NMR Predictor:Predict (works with chrome, Edge or firefox)
Category:nutrient supplements, EFSA concludes: use is of safety concern.
 
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Google Scholar:Search
Google Books:Search
Google Scholar: with word "volatile"Search
Google Scholar: with word "flavor"Search
Google Scholar: with word "odor"Search
Perfumer and Flavorist:Search
Google Patents:Search
US Patents:Search
EU Patents:Search
Pubchem Patents:Search
PubMed:Search
NCBI:Search
 
Physical Properties:
Assay: 95.00 to 100.00
Food Chemicals Codex Listed: No
Flash Point: 32.00 °F. TCC ( 0.00 °C. ) (est)
logP (o/w): -0.928 (est)
Soluble in:
 water, 12.48 mg/L @ 25 °C (est)
 
Organoleptic Properties:
Odor and/or flavor descriptions from others (if found).
 
Cosmetic Information:
None found
 
Suppliers:
American International Chemical, LLC.
Magnesium Orotate
BOC Sciences
For experimental / research use only.
bis(1,2,3,6-tetrahydro-2,6-dioxopyrimidine-4-carboxylato-N3,O4)magnesium 95%
Carbosynth
For experimental / research use only.
Magnesium Orotate
Global Calcium
Magnesium Orotate
Penta International
MAGNESIUM OROTATE
 
Safety Information:
 
Hazards identification
 
Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
None found.
GHS Label elements, including precautionary statements
 
Pictogram
 
Hazard statement(s)
None found.
Precautionary statement(s)
None found.
Oral/Parenteral Toxicity:
Not determined
Dermal Toxicity:
Not determined
Inhalation Toxicity:
Not determined
 
Safety in Use Information:
Category:
nutrient supplements, EFSA concludes: use is of safety concern.
Recommendation for magnesium orotate usage levels up to:
 not for fragrance use.
 
Recommendation for magnesium orotate flavor usage levels up to:
 not for flavor use.
 
Safety References:
European Food Safety Authority (EFSA) reference(s):

Orotic acid salts as sources of orotic acid and various minerals added for nutritional purposes to food supplements
View page or View pdf

EPI System: View
Daily Med:search
AIDS Citations:Search
Cancer Citations:Search
Toxicology Citations:Search
EPA Substance Registry Services (TSCA):34717-03-8
EPA ACToR:Toxicology Data
EPA Substance Registry Services (SRS):Registry
Laboratory Chemical Safety Summary :3036905
National Institute of Allergy and Infectious Diseases:Data
magnesium 2,4-dioxo-1H-pyrimidine-6-carboxylate
Chemidplus:0034717038
 
References:
 magnesium 2,4-dioxo-1H-pyrimidine-6-carboxylate
NIST Chemistry WebBook:Search Inchi
Pubchem (cid):3036905
Pubchem (sid):135115407
 
Other Information:
(IUPAC):Atomic Weights of the Elements 2011 (pdf)
Videos:The Periodic Table of Videos
tgsc:Atomic Weights use for this web site
(IUPAC):Periodic Table of the Elements
CHEMBL:View
HMDB (The Human Metabolome Database):Search
FDA Listing of Food Additive Status:View
ChemSpider:View
Wikipedia:View
 
Potential Blenders and core components note
None Found
 
Potential Uses:
None Found
 
Occurrence (nature, food, other):note
 not found in nature
 
Synonyms:
2,6-dioxo-1,3-dihydropyrimidine-4-carboxylic acid, 2,6-dioxo-1,3-dihydropyrimi dine-4-carboxylic acid, magnesium salt
 magnesium 2,4-dioxo-1H-pyrimidine-6-carboxylate
 magnesium bis(2,6-dioxo-1,2,3,6-tetrahydro-4-pyrimidinecarboxylate)
 magnesium bis(2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylate)
 magnesium orotate 6.26
 magnesium, bis(1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinecarboxylato-kappaN3,kappaO4)-, (T-4)-
4-pyrimidinecarboxylic acid, 1,2,3,6-tetrahydro-2,6-dioxo-, magnesium salt (2:1)
bis(1,2,3,6-tetrahydro-2,6-dioxopyrimidine-4-carboxylato-N3,O4)magnesium
 

Articles:

PubMed:[Magnesium orotate in treatment of chronic hypertension in pregnant women].
PubMed:Magnesium orotate elicits acute cardioprotection at reperfusion in isolated and in vivo rat hearts.
PubMed:[Correction of a connective tissue dysplasia in the treatment of postoperative abdominal hernias].
PubMed:[The ileocoecal valve changes in chronic constipation in children].
PubMed:[Fifteen years experience of the use of magnesium preparations in patients with mitral valve prolapse].
PubMed:[Adrenoreactivity in patients with arrhythmic syndrome associated with connective tissue dysplasia at the background of intake of the magnezium orotate].
PubMed:Perioperative metabolic therapy improves redox status and outcomes in cardiac surgery patients: a randomised trial.
PubMed:Magnesium orotate in severe congestive heart failure (MACH).
PubMed:[Basic and metabolic therapy of hypertensive disease in pregnant women].
PubMed:Targeting oxidative stress in surgery: effects of ageing and therapy.
PubMed:Magnesium orotate in severe congestive heart failure (MACH).
PubMed:The clinical application of metabolic therapy for cardiovascular disease.
PubMed:Pre-operative preparation for cardiac surgery utilising a combination of metabolic, physical and mental therapy.
PubMed:Magnesium orotate--experimental and clinical evidence.
PubMed:The principles of metabolic therapy for heart disease.
PubMed:[Clinical value of the use of magnesium orotate in adolescents with syndrome of cardiac connective tissue dysplasia].
PubMed:Assessment of treatment with orotate magnesium in early postoperative period of patients with cardiac insufficiency and coronary artery by-pass grafts (ATOMIC).
PubMed:Magnesium orotate in myocardial and neuronal protection.
PubMed:Response of the senescent heart to stress: clinical therapeutic strategies and quest for mitochondrial predictors of biological age.
PubMed:Magnesium-orotate supplementation for idiopathic infertile male patients: a randomized, placebo-controlled clinical pilot study.
PubMed:Unexpected toxicity induced by magnesium orotate treatment in congenital hypomagnesemia.
PubMed:[Clinical trial of Magnerot in the treatment of a threatened abortion after a previous delivery].
PubMed:[Passive orthostatic test in evaluation of efficiency of medical rehabilitation of flying personnel].
PubMed:[Course of the progression of experimentally induced arteriosclerotic vessel wall changes after treatment with magnesium orotate] .
PubMed:[New approaches to the treatment of patients with idiopathic mitral valve prolapse].
PubMed:On the significance of magnesium in extreme physical stress.
PubMed:Effect of orotic acid and magnesium orotate on the development and progression of the UM-X7.1 hamster hereditary cardiomyopathy.
PubMed:Effects of magnesium orotate on exercise tolerance in patients with coronary heart disease.
PubMed:Metabolic supplementation with orotic acid and magnesium orotate.
PubMed:[Morphological aspects of the effect of magnesium orotate therapy on changes in the vascular walls induced by cholesterol-rich diet].
PubMed:Morphological aspects of the effects of orotic acid and magnesium orotate on hypercholesterolaemia in rabbits.
PubMed:Effects of magnesium orotate on rat heart function.
PubMed:[Does Hepavis have value in the therapy of fatty liver caused by alcohol poisoning?].
PubMed:Lithium orotate in the treatment of alcoholism and related conditions.
PubMed:[Clinical experience report on Hepavis].
PubMed:[The effect of magnesium orotate on dental hard tissue in undernourished rats].
PubMed:The effect of kavaine and magnesium orotate combination in the psycho - organic disorders of the elderly.
PubMed:[Testing of the clinical effects of a cavain-magnesium-orotate combination in inmates of a nursing home using a double-blind study].
PubMed:Capillarographic criteria on the effect of magnesium orotate, EPL substances and clofibrate on the elasticity of blood vessels.
PubMed:[Does magnesium-orotate improve the effect of lipid lowering drugs?].
PubMed:[Experimental studies on the effect of magnesium orotate glycinate on the hemodynamics of A. coronaris and A. femoralis].
PubMed:[Effect of magnesium orotate glycinate on the brain electric activity after experimental ammonia poisoning].
PubMed:[Effect of magnesium orotate glycinate on experimental ammonia poisoning].
PubMed:[Effect of magnesium orotate and ortotic acid on the activity of lysosomal enzymes in the liver].
PubMed:[Influence of magnesium-orotate and orotic acid on learning processes in normal and neurotoxically injuried rats].
PubMed:[Pathophysiological study on lipoid metabolism in the liver under the influence of orotic acid and magnesium orotate].
PubMed:[Studies of the vegetative action mechanism of kavain and magnesium orotate].
PubMed:[The therapeutic effect of kavain and magnesium orotate on traumatic and vascular brain lesions].
PubMed:[Effect of magnesium orotate and orotic acid on induced blood pressure elevation and cardiopathogenic changes of the myocardium in animal experiments].
PubMed:[Studies of the vegetative action mechanism of kavain and magnesium orotate].
PubMed:[The effect of magnesium orotate and orotic acid on the enzyme activity of the liver. Experimental studies].
PubMed:[Arteriosclerosis, myocardial infarct and blood lipids, their therapeutic modification by magnesium orotate].
PubMed:[Causes of the multilayered effect of magnesium orotate in degenerative heart and vascular diseases (vascular sclerosis)].
 
Notes:
None found
Please share your Comments.
Email Address:
Top of Page Home
Copyright © 1980-2021 The Good Scents Company (tgsc) ™ Disclaimer Privacy Policy